• Immunotherapies are at the forefront of novel oncologic therapies, specifically inhibitors of the PD-L1/PD-1 pathway, but can be costly and toxic to patients.
• We examined if quantitative texture analysis (QTA) of baseline diagnostic CT scans could serve as a predictive biomarker for treatment response to PD-L1/PD-1 • Diagnostic CT scans of the chest, abdomen, and pelvis • For lung lesions, mean pixel density was predictive of response (Mann-Whitney Z = 2.6, p = 0.0092 at a threshold of mean pixel density of 11.92 p < 0.0001 ) • Although a universal predictive biomarker was not found for all lesions, there was a significant difference in texture analysis of lung metastases.
Discussion and Conclusions

Methods
• 20 patients, 10 responders, 10 nonresponders based on RECIST criteria • Variety of primary malignancies and previous treatments • CT scans of chest/abdomen/pelvis acquired from Honor Health and Scottsdale Medical Imaging • Regions of interest were placed around each lesion • Spatial scale factors of 0-6 pixels were used to filter the images • Histograms are developed from the filtered data based on a number of measures.
Introduction
• QTA is a novel imaging technique that evaluates lesions based on tumor heterogeneity and creates histogram data based on skewness, kurtosis, mean pixel density, entropy, mean positive pixels, and standard deviation.
• PD-L1 is often expressed on tumor cells • PD-L1 inactivates cytotoxic T-cells (CTL) by binding PD-1, which if found on the CTL surface • Blocking this pathway would dampen the inhibitory effect • PD-L1/PD-1 inhibitors are associated with significant gastrointestinal and endocrine side effects • Biomarkers serve to minimize side effects, invasive procedures, and optimize treatment strategies.
• We hypothesize that QTA would uncover a predictive biomarker for immunotherapy response Acknowledgements I wish to thank my mentor Dr. Ron Korn for his guidance and support during this project. 
Results
